Search Results

The Laserex LP4532 Ophthalmic Laser is intended for use in the treatment of ocular pathology

The Laserex LP4532 is indicated for use in photocoagulation of both anterior and posterior segments of the eye including:

• Retinal photocoagulation, pan retinal photocoagulation and intravitreal endophotocognilation of vascular and structural abnormalities of the retina and choroid including:
  • proliferative and nonproliferative diabetic retinopathy:
  • choroidal neovascularization;
  • branch retinal vein occlusion;
  • age-refated macular degeneration;
  • retinal tears and detachments;
  • retinopathy of prematurity;
  • macular grid;
  • macular focal;
• Iridotomy, tridectorny, suturelysis and trabeculoplasty in angle closure glaucoma and open angle glaucoma

Not Found

The provided text is a 510(k) premarket notification letter from the FDA to Ellex Medical Pty. Ltd. regarding their Laserex LP4532 Ophthalmic Laser. This document is a regulatory approval letter and an "Indications for Use" statement, not a scientific study report or clinical trial summary.

Therefore, the document does not contain the information requested about acceptance criteria, device performance, study details (sample sizes, data provenance, expert qualifications, adjudication methods), MRMC studies, standalone performance, or training set details.

The letter confirms that the FDA has reviewed the 510(k) submission and determined the device to be substantially equivalent to legally marketed predicate devices for the stated indications for use. It lists the medical conditions the laser is intended to treat, such as various retinal pathologies and glaucoma treatment procedures, but it does not provide data or a study description to prove performance against specific acceptance criteria.

To answer your request, a different type of document, such as a clinical study report or a summary of safety and effectiveness, would be needed.

Ask a specific question about this device